Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Feb 4:2019:4130757.
doi: 10.1155/2019/4130757. eCollection 2019.

Combination Treatments of Plasma Exchange and Umbilical Cord-Derived Mesenchymal Stem Cell Transplantation for Patients with Hepatitis B Virus-Related Acute-on-Chronic Liver Failure: A Clinical Trial in China

Wen-Xiong Xu #  1   2 , Hong-Liang He #  3 , Shun-Wen Pan  2   4 , Yuan-Li Chen  1   2 , Mei-Ling Zhang  1   2 , Shu Zhu  1   2 , Zhi-Liang Gao  1   2 , Liang Peng  1   2 , Jian-Guo Li  1   2
Affiliations

Combination Treatments of Plasma Exchange and Umbilical Cord-Derived Mesenchymal Stem Cell Transplantation for Patients with Hepatitis B Virus-Related Acute-on-Chronic Liver Failure: A Clinical Trial in China

Wen-Xiong Xu et al. Stem Cells Int. .

Abstract

Background: Hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF) is a common type of liver failure with a high mortality. This study aimed at investigating the safety and efficacy of the combination treatment of plasma exchange (PE) and umbilical cord-derived mesenchymal stem cell (UC-MSCs) transplantation for HBV-ACLF patients.

Methods: A total of 110 HBV-ACLF patients treated in our hospital from January 2012 to September 2017 were enrolled into this trial and divided into the control group (n = 30), UC-MSC group (n = 30), PE group (n = 30), and UC-MSC + PE group (n = 20) based on their treatments. The hepatic function, coagulation, and virological and immunological markers were assessed at baseline and 30, 60, 90, 180, and 360 days. The endpoint outcomes were death and unfavorable outcome (need for liver transplantation or death).

Results: The UC-MSC + PE group had the lowest rates of death and unfavorable outcome at 30 days, 60 days, and 90 days posttreatment among the four groups, but the difference did not reach significances. The multivariate logistic regression analysis demonstrated that hemoglobin, prothrombin activity, and MELD (model for end-stage liver disease) score were the independent factors associated with the unfavorable outcome (all P < 0.05). The levels of total bilirubin, alanine aminotransferase, aspartate transaminase, and MELD score were significantly decreased during treatments (all P < 0.05).

Conclusion: UC-MSCs combined with PE treatment had good safety but cannot significantly improve the short-term prognosis of HBV-ACLF patients with as compared with the single treatment. The long-term efficacy should be further evaluated. This trial is registered with registration no. NCT01724398.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The consort diagram and flow chart of analysis.
Figure 2
Figure 2
The Kaplan-Meier survival function among four treatment groups to unfavorable outcomes (a) and overall survival (b).
Figure 3
Figure 3
Biochemical markers of hepatic function and the severity of liver disease were shown from baseline to 90 days, including AST (a), ALT (b), prothrombin activity (c), and MELD score (d).
Figure 4
Figure 4
The changes of hepatic function markers were recorded before and, after 3 times of PE treatment, including AST (a), ALT (b), prothrombin activity (c), and MELD score (d).
See this image and copyright information in PMC

References

    1. Hernaez R., Solà E., Moreau R., Ginès P. Acute-on-chronic liver failure: an update. Gut. 2017;66(3):541–553. doi: 10.1136/gutjnl-2016-312670. - DOI - PMC - PubMed
    1. Wu J., Chen L., Chen Y., Yang J., Wu D. Serum ferritin concentration predicts mortality in patients with hepatitis B virus-related acute on chronic liver failure. Archives of Medical Research. 2014;45(3):251–256. doi: 10.1016/j.arcmed.2014.03.004. - DOI - PubMed
    1. Wu T., Li J., Shao L., et al. Development of diagnostic criteria and a prognostic score for hepatitis B virus-related acute-on-chronic liver failure. Gut. 2018;67(12):2181–2191. doi: 10.1136/gutjnl-2017-314641. - DOI - PubMed
    1. Li H., Chen L. Y., Zhang N. N., et al. Characteristics, diagnosis and prognosis of acute-on-chronic liver failure in cirrhosis associated to hepatitis B. Scientific Reports. 2016;6(1, article 25487) doi: 10.1038/srep25487. - DOI - PMC - PubMed
    1. the APASL ACLF Working Party, Sarin S. K., Kedarisetty C. K., et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL) 2014. Hepatology International. 2014;8(4):453–471. doi: 10.1007/s12072-014-9580-2. - DOI - PubMed

Associated data

LinkOut - more resources